Table 2.

In vivo antitumor activity of AMN107 in SCID mice bearing KBM5 CML cells

TreatmentNo. mice per groupSurvival time, range (d)Median survival time (d)Treated survival as percentage of control survival*
Control823-3227
AMN107, 10 mg/kg933-4939144%
AMN107, 20 mg/kg939-5743159%
AMN107, 30 mg/kg941-7849182%
  • * Median survival time of treated mice as percentage of median survival time of control mice.